Loading…
Nevada Mining Townsite Conveyance Act
Legislative Progress
Momentum (last 30 days)
0
score
0 actions · 0 new cosponsors · 0 votes
Speed vs cohort
0pct
0d open
vs 4,048 other S bills in the 111th — cohort avg 29d
No CRS summary is available for this bill yet. The source title, actions, sponsors, and text versions below come from Congress.gov.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (4)
2009 · fourth_quarter · Health Issues
Advocate for cost containment initiatives such as comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development and utilization of a state and/or federal prescription drug formulary (including, but not limited to, HR 3200).
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE, White House Office
2009 · third_quarter · Health Issues
Advocate for cost containment initiatives such as comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development and utilization of a state and/or federal prescription drug formulary (including, but not limited to, HR 3200).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, White House Office
2009 · second_quarter · Health Issues
Advocate for cost containment initiatives such as comparative effectiveness research and patient safety (including but not limited to S. 3408); advocate for policies related to the development of public standards for food ingredients and safety (including but not limited to S. 3385).
Client expense: Not reported · Firm income: $50,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
Pandemic preparedness; Accutane safety; diabetes issues; Tamiflu; Reimbursement and other issues related to anemia and arthritis drugs. Planning treatment protocols for patiens requireing cancer drugs; issues related to government purchases of pandemic drugs; community relations and outreach to develop and maintain relationships with minority groups and health organizations to promote diabetes awareness. Public policy such as promoting initiatives and strategizing on the most effective approaches to tell the story of Roche's efforts to address and try to resolve health disparities affecting minority communities. Addressed funding for pandemic flu and emergency preparedness. H.R. 1585, The FIT Kids Act, issues addressing childhood obesity; addressed issues pertaining to comprehensive health care reform; comparative effectiveness research. S.1213, Patient-Centered outcomes Research Act of 2009 and S. 3408, H.R.1548, Pathway for Biosimilars Act; and S. 525, Pharmaceutical Market Access & Drug Safety Act of 2009. Track and monitor health care reform including H.R. 1427 and S. 726, Promoting Innovation and Access to Life-Saving Medicince Act General support for Hoffmann-LaRoche products.
Client expense: $1,456,892 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
American Recovery and Reinvestment Act of 2009 (provisions related to health IT, comparative effectiveness, and cancer research), Health Care Reform draft legislation, Comparative effectivess (S. 3408), Amendment to the Federal Food, Drug, and Cosmetic Act to improve the safety of food, drugs, devices, and cosmetics in the global market (HR 759), 21st Century Cancer ALERT Act (S 717)
Client expense: $100,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2009 · second_quarter · Health Issues
general healthcare issues related to pharmaceutical and biological products; Federal, Food Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Reserach Act (S.3408); Enhanced Health Care Value for All Act (HR2184); Promoting Innovation and Access to Life-saving Medicine Act (HR1427/S.726); Biologics Price Competition and Innovation Act of 2007 (S.1695); Pathway for Biosimilars Act (HR1548); Health Reform; Affordable Health Choices Act
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
American Recovery and Reinvestment Act of 2009 (provisions related to Health IT, comparative effectiveness and cancer research), general healthcare reform dialogue, Comparative Effectiveness (S. 3408)
Client expense: $110,000 · Firm income: Not reported
Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
2009 · first_quarter · Health Issues
General healthcare issues related to pharmaceutical and biological products; Federal, Food, Drug and Cosmetic Act (21 USC 9); Public Health Service Act (42 USC 6A); FDA Globalization Act (H.R. 759); Follow-on Biologics; Comparative Effectiveness: Comparative Effectiveness Research Ace (S. 3408); Enhanced Health Care Value for All Act (H.R. 2184); Promoting Innovation and Access to Life-saving Medicine Act (H.R. 1427/S.726); Biologics Price Competition and Innovation Act (S.1695)
Client expense: Not reported · Firm income: $20,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE